| Name | Title | Contact Details |
|---|
Alexza Pharmaceuticals, located in Mountain View, CA, is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza`s products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.
LUMICKS is the leading supplier of Dynamic Single-Molecule and Cell Avidity analysis instruments` Our instruments enable – for the first time – the analysis of complex dynamic details related to the behavior and interaction of single molecules and cells` Built upon innovative and Nobel Prize-winning technologies, such as optical tweezers (Nobel Prize for Physics 2018), and STED super-resolution (Nobel Prize for Chemistry 2014), our tools enable the understanding of life to the smallest detail` Our goal is to improve human health by unlocking the power of Dynamic Single–Molecule and Cell Avidity analysis to provide unparalleled insight into the fundamental cause of disease and potential for drug optimization` These technologies are rapidly evolving as a mainstream approach in academic and pharma research for the study of DNA-protein interactions, molecular motor activity, protein folding, and cell-cell interactions`
Allcells LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange.
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.